Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederroche.com
Investor Update
Get the latest updates from Investor Update directly as they happen.
Follow now 350 followers
Latest posts
Last updated 9 days ago
Roche’s Susvimo maintains vision over five years with two refills per year in people with neovascular age-related macular degeneration (nAMD)
9 days ago
Susvimo is the only continuous delivery treatment to provide reliable, long-term vision...
Roche presents new insights in Alzheimer’s disease research across its diagnostics and pharmaceutical portfolios at AAIC
13 days ago
Trontinemab’s Phase Ib/IIa Brainshuttle™ AD study continues to show rapid and robust...
Roche provides regulatory update on Elevidys™ gene therapy for Duchenne muscular dystrophy in the EU
16 days ago
EMA’s CHMP issued an opinion not to recommend Elevidys™ (delandistrogene moxeparvovec) for...
Invitation to Roche’s Pharma Day 2025
16 days ago
The Roche Investor Relations team would like to invite you to the...
[Ad hoc announcement pursuant to Art. 53 LR] Roche continues strong momentum with 7% growth (CER) in the first half of 2025
17 days ago
Group sales grew by 7%1 at constant exchange rates (CER; 4% in...
Roche receives CE Mark for minimally invasive blood test to help rule out Alzheimer’s disease
18 days ago
Elecsys pTau181 is the first In Vitro Diagnostic Regulation (IVDR) certified test...
European Commission approves Roche’s Itovebi for people with ER-positive, HER2-negative, advanced breast cancer with a PIK3CA mutation
18 days ago
Approval based on INAVO120 data showing the Itovebi™ (inavolisib)-based regimen more than...
Roche’s Board of Directors proposes exchange of Genussscheine for participation certificates (Partizipationsscheine)
19 days ago
Participation certificates (Partizipationsscheine) with a nominal value of CHF 0.001 each will...
[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on astegolimab in chronic obstructive pulmonary disease
20 days ago
The pivotal phase IIb ALIENTO study met the primary endpoint of a...
Roche provides update on supplemental Biologics License Application for Columvi combination for people with relapsed or refractory diffuse large B-cell lymphoma
23 days ago
Basel, 18 July 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced...
Reminder: Invitation to Roche’s Half Year Results 2025 Presentation
24 days ago
Roche will publish its Half Year Results of 2025 prior to the...
Invitation to Roche’s Half Year Results 2025 Presentation
about 2 months ago
Roche will publish its Half Year Results of 2025 prior to the...